Stock Events

Stock Events

Swedish Orphan Biovitrum AB 

$47.48
15
+$0.13+0.26% Tuesday 15:48

Statistics

Day High
47.48
Day Low
47.48
52W High
47.48
52W Low
27
Volume
200
Avg. Volume
-
Mkt Cap
0
P/E Ratio
169.11
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-8.3
-3.77
0.75
5.28
Expected EPS
3.117342522866
Actual EPS
N/A

Financials

14.92%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
4.72BRevenue
704.64MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIOVF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals is a competitor because it also focuses on rare diseases, similar to Swedish Orphan Biovitrum, with a strong emphasis on cystic fibrosis treatments.
Biogen
BIIB
Mkt Cap27.62B
Biogen competes in the rare disease space, particularly in areas like spinal muscular atrophy and multiple sclerosis, overlapping with some of Swedish Orphan Biovitrum's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences competes with Swedish Orphan Biovitrum through its focus on antiviral drugs for HIV, hepatitis B, and hepatitis C, as well as its expansion into other areas of high unmet medical need.
AMGEN
AMGN
Mkt Cap178B
Amgen competes in the biopharmaceutical field, focusing on treatments for serious illnesses, including areas that overlap with Swedish Orphan Biovitrum's focus on rare diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is a competitor due to its focus on developing and commercializing treatments for eye diseases, rare diseases, and cancer, areas that Swedish Orphan Biovitrum also targets.
Novo Nordisk
NVO
Mkt Cap194.57B
Novo Nordisk is a leading company in diabetes care but also competes in the biopharmaceutical space, including treatments for rare blood disorders, overlapping with Swedish Orphan Biovitrum's market.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is a broad-based competitor, with a significant presence in rare diseases through its Rare Disease unit, making it a competitor across several of Swedish Orphan Biovitrum's therapeutic areas.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca, especially after its acquisition of Alexion Pharmaceuticals, competes in the rare disease market, directly challenging Swedish Orphan Biovitrum's portfolio of rare disease therapies.

About

There is no Profile data available for B6E.SG.
Show more...
CEO
Dr. Guido Oelkers Ph.D.
Employees
1895
Country
Sweden
ISIN
SE0000872095

Listings

MI
IT
1SOBI.MI
MU
DE
B6E.MU
STU
DE
B6E.STU
ST
SE
SOBI.ST

0 Comments

Share your thoughts

FAQ

What is Swedish Orphan Biovitrum AB stock price today?▼
The current price of BIOVF is $47.48 USD — it has increased by +0.26% in the past 24 hours. Watch Swedish Orphan Biovitrum AB stock price performance more closely on the chart.
What is Swedish Orphan Biovitrum AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Swedish Orphan Biovitrum AB stocks are traded under the ticker BIOVF.
Is Swedish Orphan Biovitrum AB stock price growing?▼
BIOVF stock has risen by +10.02% compared to the previous week, the month change is a +19.07% rise, over the last year Swedish Orphan Biovitrum AB has showed a +55.66% increase.
When is the next Swedish Orphan Biovitrum AB earnings date?▼
Swedish Orphan Biovitrum AB is going to release the next earnings report on July 16, 2026.
What were Swedish Orphan Biovitrum AB earnings last quarter?▼
BIOVF earnings for the last quarter are 0.4 USD per share, whereas the estimation was 0.38 USD resulting in a +4.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Swedish Orphan Biovitrum AB revenue for the last year?▼
Swedish Orphan Biovitrum AB revenue for the last year amounts to 4.72B USD.
What is Swedish Orphan Biovitrum AB net income for the last year?▼
BIOVF net income for the last year is 704.64M USD.
How many employees does Swedish Orphan Biovitrum AB have?▼
As of May 06, 2026, the company has 1,895 employees.
In which sector is Swedish Orphan Biovitrum AB located?▼
Swedish Orphan Biovitrum AB operates in the Health & Wellness sector.
When did Swedish Orphan Biovitrum AB complete a stock split?▼
Swedish Orphan Biovitrum AB has not had any recent stock splits.
Where is Swedish Orphan Biovitrum AB headquartered?▼
Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden.